Stocks closed higher on Wall Street as the Trump administration sought to win more deals with global trading partners. The S&P 500 rose 0.6% Wednesday. The Dow Jones Industrial Average added 0.5%, and the Nasdaq composite rose 0.9%. Nvidia became the first public company to top $4 trillion in value. Merck rose after announcing it would buy Verona Pharma, a U.K. company that focuses on respiratory diseases. Copper prices eased after spiking a day earlier as President Donald Trump said he would impose 50% tariffs on imports of the metal. Treasury yields slipped in the bond market.
THIS IS A BREAKING NEWS UPDATE. AP鈥檚 earlier story follows below.
U.S. stocks are higher in afternoon trading Wednesday as Wall Street weighs the latest developments in the Trump administration's bid to win more deals with global trading partners.
The S&P 500 was up 0.5%, coming off a slight loss a day earlier. The benchmark index remains near the it set last week after a better-than-expected .
The Dow Jones Industrial Average was up 179 points, or 0.4%, as of 2:52 p.m. Eastern time, and the Nasdaq composite was 0.8% higher.
Gains in technology and communication services stocks helped drive the market higher, outweighing declines in energy and other sectors.
Nvidia rose 1.7%. The chipmaker became as its share price briefly topped $164 each in the early going. Shares in the AI boom poster child were going for around $14 per share at the start of 2023.
Elsewhere among Big Tech stocks, Microsoft was up 1.2%, Meta rose 2.1% and Google parent Alphabet added 1.2%.
Amazon rose 1.5% a day after the online retail giant , extending it for the first time to four days.
In bond market trading, the yield on the 10-year Treasury slid to 4.34% from 4.40% late Tuesday.
Wall Street has been focused this week on President Donald Trump's to use threats of higher tariffs on goods imported into the U.S. in hopes of securing new trade agreements with countries around the globe.
Wednesday was initially set as a deadline by Trump for countries to make deals with the U.S. or face heavy increases in tariffs. But with just announced since April, one with the United Kingdom and one with Vietnam, the window for negotiations has been extended to Aug. 1.
This latest phase in the White House鈥檚 trade war heightens the threat of potentially more severe tariffs that鈥檚 been hanging over the global economy. Higher taxes on imported goods could hinder economic growth, if not increase recession risks.
On Tuesday, Trump said he would be announcing tariffs on pharmaceutical drugs at a 鈥渧ery, very high rate, like 200%.鈥� He also said he would sign an executive order placing a 50% tariff on copper imports, matching the rates charged on steel and aluminum.
Copper prices eased Wednesday after spiking a day earlier. Shares in mining company Freeport-McMoRan were down 2%.
Financial markets swooned from day-to-day for weeks after the White House rolled out its proposed tariff hikes in the spring. With the new batch of U.S. taxes on imports not set to kick in until next month, that gives Wall Street a breather just as the next corporate earnings season is set to begin.
鈥淚 think most people are tired of tariff news and they鈥檙e starting to realize it just doesn鈥檛 matter much,鈥� said Jay Hatfield, CEO of Infrastructure Capital Advisors. 鈥淲e鈥檙e pretty bullish about earnings. I think the rest of the market is too."
Wall Street analysts predict that companies in the S&P 500 will deliver a combined 5% annual growth in second-quarter earnings, according to FactSet. That would mark the lowest growth rate for the index since the fourth quarter of 2023.
Delta Air Lines kicks off earnings season on Thursday, with most analysts expecting the airline鈥檚 second-quarter profit to decline from a year ago. Delta and other major U.S. carriers have this year as consumers pull back on travel and other nonessential spending due to uncertainty about how Trump鈥檚 tariffs will affect their budgets.
Outside of trade talks, some corporate news surfaced Wednesday after a typically quiet early summer stretch.
Pharmaceutical giant , a U.K. company that focuses on respiratory diseases, in an approximately $10 billion deal. If approved by Verona shareholders and U.K. officials, Merck will get access to Verona鈥檚 chronic obstructive pulmonary disease medication Ohtuvayre. Verona shares jumped more than 20% on the news, while Merck shares were up 3.1%.
In overseas markets, stock indexes closed broadly higher in Europe after a mixed finish in Asia.
Alex Veiga, The Associated Press
